Related Experiment Video

Updated: May 25, 2026

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells
11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

Integrin inhibitors as a therapeutic agent for ovarian cancer

Kenjiro Sawada1, Chifumi Ohyagi-Hara, Tadashi Kimura

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Journal of Oncology
|January 12, 2012
PubMed

Insights

Targeting integrins shows promise for treating ovarian cancer metastasis, despite current inhibitors lacking favorable results. Further research into integrin-targeted therapies is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis

Background:

  • Ovarian cancer has a low cure rate (30%) with high relapse rates in advanced stages.
  • Integrins play a critical role in the initial steps of ovarian cancer metastasis, specifically cancer cell attachment to the peritoneum and omentum.
  • Anti-angiogenic therapies have shown positive clinical results, suggesting targeted approaches are viable.

Purpose of the Study:

  • To review current knowledge on integrin biology in ovarian cancer metastasis.
  • To summarize therapeutic strategies utilizing integrin inhibitors for ovarian cancer.
  • To assess the potential of integrin-targeted therapies for future clinical investigation.

Main Methods:

  • Literature review of integrin biology in ovarian cancer.
  • Analysis of clinical studies involving integrin inhibitors.
  • Evaluation of therapeutic approaches targeting integrins in ovarian cancer metastasis.

Main Results:

  • Integrin inhibitors have demonstrated effectiveness in blocking cancer progression in clinical studies.
  • Despite promising preclinical data, no integrin inhibitors have yielded favorable clinical outcomes to date.
  • The role of integrins in ovarian cancer cell adhesion and metastasis is well-established.

Conclusions:

  • Targeting integrins represents a feasible and promising therapeutic strategy for ovarian cancer.
  • Integrin-targeted therapies warrant further exploration and clinical investigation for improved treatment efficacy.
  • Understanding integrin function in metastasis is key to developing novel ovarian cancer treatments.

More Related Videos

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer07:46

In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer

Published on: August 17, 2010

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...